Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
ovarian cancer
Journal
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
03
02
2020
revised:
25
02
2020
accepted:
27
02
2020
pubmed:
12
4
2020
medline:
29
9
2021
entrez:
12
4
2020
Statut:
ppublish
Résumé
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have transformed the treatment landscape in front-line and recurrent high-grade serous ovarian cancer. Maintenance strategies with PARPi have been assessed in randomized phase III trials in ovarian cancer; switch maintenance in the case of olaparib, niraparib, and rucaparib; and concurrent followed by continuation maintenance with veliparib. These studies have shown progression-free survival advantage with PARPi maintenance, with no major adverse changes in the quality of life; however, overall survival data remain immature to date. PARPi have also been incorporated in clinical practice as a single-agent treatment strategy in high-grade serous ovarian cancer, mainly in women who harbor alterations in the
Identifiants
pubmed: 32276934
pii: ijgc-2020-001288
doi: 10.1136/ijgc-2020-001288
pmc: PMC7398227
doi:
Substances chimiques
Poly(ADP-ribose) Polymerase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
903-915Commentaires et corrections
Type : CommentIn
Informations de copyright
© IGCS and ESGO 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: VB was previously on the advisory board for olaparib with AZ and received a previous honorarium for a presentation with AZ. AO is on the steering committee of GSK, AZ and Clovis (uncompensated), and is PI on clinical trials for AZ, GSK, and Clovis. SL declares honaria from Roche, AZ, GSK, Merck, and is Co-Inv and PI on a number of different clinical trials.
Références
PLoS One. 2013;8(1):e54161
pubmed: 23326593
Lancet Oncol. 2019 May;20(5):636-648
pubmed: 30948273
Lancet Oncol. 2015 Jan;16(1):87-97
pubmed: 25481791
N Engl J Med. 2019 Dec 19;381(25):2403-2415
pubmed: 31562800
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Clin Cancer Res. 2018 Sep 1;24(17):4066-4071
pubmed: 29650751
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Mol Cell. 2015 Sep 17;59(6):984-97
pubmed: 26321255
Cell Res. 2008 Jan;18(1):99-113
pubmed: 18166982
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
J Palliat Med. 2019 Aug;22(8):977-980
pubmed: 30839241
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
N Engl J Med. 2019 Dec 19;381(25):2471-2474
pubmed: 31851805
Invest New Drugs. 2020 Feb;38(1):181-193
pubmed: 31650446
Am J Gastroenterol. 2017 Jul;112(7):988-1013
pubmed: 28631728
Clin Transl Sci. 2019 Jan;12(1):58-65
pubmed: 30427584
Lancet Oncol. 2011 Sep;12(9):852-61
pubmed: 21862407
Circulation. 2018 Oct 23;138(17):e426-e483
pubmed: 30354655
Clin Cancer Res. 2013 Oct 1;19(19):5485-93
pubmed: 23922302
Am J Hosp Palliat Care. 2019 Sep;36(9):815-819
pubmed: 30754984
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
Mol Cancer Res. 2019 Feb;17(2):409-419
pubmed: 30429212
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Crit Rev Oncol Hematol. 2018 Nov;131:83-89
pubmed: 30293710
J Med Genet. 2012 Jul;49(7):422-8
pubmed: 22652532
Gynecol Oncol. 2017 Nov;147(2):267-275
pubmed: 28882436
Lancet Oncol. 2018 Aug;19(8):1117-1125
pubmed: 30026000
J Natl Compr Canc Netw. 2019 Jan;17(1):64-84
pubmed: 30659131
Lancet. 2010 Jul 24;376(9737):245-51
pubmed: 20609468
Lancet Oncol. 2018 Aug;19(8):1126-1134
pubmed: 30026002
Oncology (Williston Park). 2016 Feb;30(2):166-76
pubmed: 26892153
J Clin Oncol. 2019 Sep 20;37(27):2449-2459
pubmed: 31403862
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
CA Cancer J Clin. 2019 Jul;69(4):280-304
pubmed: 31099893
Gynecol Oncol. 2016 Feb;140(2):199-203
pubmed: 26723501
Clin Cancer Res. 2017 Aug 1;23(15):4095-4106
pubmed: 28264872
Ann Oncol. 2018 Aug 1;29(8):1784-1792
pubmed: 29767688
Diabetes. 2006 Jun;55(6):1686-94
pubmed: 16731831
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
J Clin Oncol. 2012 Feb 1;30(4):372-9
pubmed: 22203755
Cancers (Basel). 2019 Mar 23;11(3):
pubmed: 30909618
Oncology (Williston Park). 2019 Feb 15;33(2):58-61
pubmed: 30784030
Pharmacoeconomics. 2019 Mar;37(3):391-405
pubmed: 30478649
Clin Cancer Res. 2017 Aug 1;23(15):4086-4094
pubmed: 28223274
Lancet Oncol. 2019 Oct;20(10):1409-1419
pubmed: 31474354
Int J Gynecol Cancer. 2020 Jan;30(1):89-93
pubmed: 31792084
Pharmacoeconomics. 2019 Aug;37(8):1065-1067
pubmed: 31172449
Am Soc Clin Oncol Educ Book. 2019 Jan;39:e152-e166
pubmed: 31099646
Gynecol Oncol. 2018 Apr;149(1):214-220
pubmed: 29397193
J Clin Oncol. 2018 Jan 20;36(3):283-299
pubmed: 29182495
Ann Oncol. 2019 Apr 1;30(4):551-557
pubmed: 30753272
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579